Alicia Bigica

The study did not meet its primary end point of change from baseline in Performance of the Upper Limb 2.0 score at 1 year.

The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.

The committee all agreed that tofersen presents a favorable risk-benefit profile in this particularly challenging patient population.

Study results suggest that selected interventions should be based on phenotypic differences and treatment goals.

Sacco, who also served as president of the American Heart Association/ American Stroke Association, succumbed to a brain tumor on January 17, 2023.

The trial, launched through a partnership between Cure Rare Disease and UMass Chan Medical School, assessed CRD-TMH-001, a CRISPR-based gene therapy.

The BTK inhibitor is currently the subject of several ongoing phase 3 clinical trials that include more than 2000 patients currently on the therapy.

More than $5.2 million in new, unused DMTs were collected from patients with MS over the course of 1 year—from only 1 neuroimmunologist.

The agency pushed the PDUFA date back citing new data analyses that constitute a significant amendment to the NDA.

The oral version offers the same efficacy as the previously approved intravenous treatment.

The associate director of the Neuromyelitis Optica Clinic and Research Unit at Mass General spoke about some of the unmet needs and unanswered questions surrounding NMO management.

The results demonstrate a positive change in patients with previous disease-modifying drug failures.

The VA health system, which provides medical benefits to more than 9 million veterans, rebuked the drug due to lack of demonstrated efficacy and safety concerns.

These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more unified, global approach to diagnosing and monitoring patients with multiple sclerosis.

Ian Kremer, executive director of the LEAD Coalition, discusses the need for improved access to social services surrounding the diagnosis and management of Alzheimer disease.

Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.

Health care professionals and a caregiver discuss the overall burden of hallucinations and delusions associated with dementia-related psychosis, explore unmet needs in diagnosis and management of these symptoms, and discuss the need for increased dialogue between clinicians and caregivers.

Constantino Iadecola, MD, discusses the interaction of vascular risk factors and the shortcomings of our current clinical approach to Alzheimer disease.

The drug, marketed as Wakix, was previously approved for the treatment of excessive daytime sleepiness in adults with narcolepsy.

The device is the first FDA-approved trigeminal nerve stimulator for migraine treatment available without a prescription.

The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD.

The drug is indicated in patients with a confirmed mutation in the DMD gene that is amenable to exon 53 skipping.

Kathleen Digre, MD, past president of the American Headache Society, discusses the barriers to correct identification and treatment of eye symptoms in people with migraine.

A PDUFA date has been scheduled for March 7, 2021, but the agency said it would consider an even more expedited review if warranted.

The approval also expands the age range of all Epidiolex indications to include patients age 1 and older.

Data demonstrate a long-term, positive effect of the drug on cognitive function in patients with multiple sclerosis.

This year, the World Federation of Neurology partnered with the International Parkinson and Movement Disorder Society to spotlight advancements in Parkinson disease.

Previous exclusions limiting use of the drug in spasticity caused by cerebral palsy have been lifted.

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.